Literature DB >> 27021579

The three tiers of screening for sarcoidosis organ involvement.

Marc A Judson1.   

Abstract

Sarcoidosis may involve any organ in the body. Organ involvement with sarcoidosis may go undetected. This manuscript addresses a suggested approach to screening for sarcoidosis organ involvement. As sarcoidosis organ involvement may never cause symptoms or clinical problems, it is not always necessary to expend the time or expense to detect all organs involved with sarcoidosis. On the other hand, some forms of sarcoidosis organ involvement may have potentially severe consequences such as permanent vision impairment from eye sarcoidosis and sudden death from cardiac sarcoidosis. We believe it useful to describe three tiers of screening for sarcoidosis organ involvement. The first tier of screening involves eliciting a medical history and performing a physical examination. This is a useful screen for all organs. The second tier of screening involves performing specific laboratory tests to search for specific sarcoidosis organ involvement, even if there is no clinical sign or symptom to suggest involvement of that organ. Such screening is only recommended for a limited number of specific organs. The third tier of screening is complex and involves the performance of multiple tests/algorithms or examinations by subspecialists to search for specific organ involvement. The third tier of screening is used to evaluate eye sarcoidosis, vitamin D dysregulation associated with sarcoidosis, and cardiac sarcoidosis. It is hoped that this approach to screening for sarcoidosis organ involvement will be a springboard for rigorous examination of this process that is likely to benefit sarcoidosis patients.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diagnosis; Organ involvement; Sarcoidosis; Screening; Symptoms

Mesh:

Year:  2016        PMID: 27021579     DOI: 10.1016/j.rmed.2016.02.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Risk of gastrointestinal events among patients with sarcoidosis: a population-based study 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Eric L Matteson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  A case report of steroid resistant cardiac sarcoidosis successfully managed with methotrexate.

Authors:  Olga Grabowska; Magdalena M Martusewicz-Boros; Dorota Piotrowska-Kownacka; Elżbieta Wiatr
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  Cardiac Involvement in Sarcoidosis Deaths in Wayne County, Michigan: A 20-Year Retrospective Study.

Authors:  Milad Webb; Kyle S Conway; Martin Ishikawa; Francisco Diaz
Journal:  Acad Forensic Pathol       Date:  2018-08-31

4.  Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.

Authors:  Elyse E Lower; Madison Sturdivant; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

5.  Bone marrow involvement in sarcoidosis: an elusive extrapulmonary manifestation.

Authors:  J Isaac Peña-Garcia; Sana Shaikh; Bhishma Barakoti; Christos Papageorgiou; Alexandre Lacasse
Journal:  J Community Hosp Intern Med Perspect       Date:  2019-04-12

6.  Clinical characteristics and outcomes of Korean patients with sarcoidosis.

Authors:  Ho Jeong Kim; Hyeong Min Kim; Jin Woo Song
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

7.  Prevalence of cardiac sarcoidosis in white population: a case-control study: Proposal for a novel risk index based on commonly available tests.

Authors:  Magdalena M Martusewicz-Boros; Piotr W Boros; Elżbieta Wiatr; Jacek Zych; Dorota Piotrowska-Kownacka; Kazimierz Roszkowski-Śliż
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  Clinical characteristics and organ system involvement in sarcoidosis: comparison of the University of Minnesota Cohort with other cohorts.

Authors:  Hok Sreng Te; David M Perlman; Chetan Shenoy; Daniel J Steinberger; Rebecca J Cogswell; Henri Roukoz; Erik J Peterson; Lin Zhang; Tadashi L Allen; Maneesh Bhargava
Journal:  BMC Pulm Med       Date:  2020-06-01       Impact factor: 3.317

Review 9.  Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns.

Authors:  Marc A Judson
Journal:  F1000Res       Date:  2019-12-30

Review 10.  A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.

Authors:  Andrea S Melani; Albano Simona; Martina Armati; Miriana d'Alessandro; Elena Bargagli
Journal:  Pulm Ther       Date:  2021-06-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.